期刊文献+

咪唑斯汀缓释片稳定性分析法——HPLC法 被引量:5

The HPLC method developed for the stability study of mizolastine sustained-release tablet
下载PDF
导出
摘要 目的 :建立咪唑斯汀缓释片的稳定性分析方法。方法 :采用高效液相色谱法。色谱柱为PhenomenexprodigyODS3 (2 5 0mm× 4 6mm ,5 μm) ;流动相 :甲醇 pH 4 0缓冲液 (7∶3) ;检测波长 2 80nm ;流速 1 0mL·min-1;外标法峰面积定量。结果 :咪唑斯汀保留时间约为 8 6min ,中间体、辅料、分解产物等对主药测定无干扰 ;咪唑斯汀浓度在 3~ 2 4 μg·mL-1范围内线性关系良好 ,回归方程为A =10 0 0 38 0 5C +6 5 5 6 ,r =0 99999;最低检出浓度为6 0ng·mL-1;日内、日间精密度 (RSD)分别为 0 39% (n =5 )和 0 5 6 % (n =5 ) ,重现性试验RSD =0 5 6 % (n =9) ;方法平均回收率为 99 4 7%~ 10 1 97% (n =5 ) ;模拟制剂平均回收率为 10 0 0 4 % (n =9)。结论 :该法灵敏、准确、专属性强 ,可用于咪唑斯汀片的稳定性研究。 Objective:To establish a HPLC method for the stability study of mizolastine sustained-release tablet.Methods:The chromatographic column was a Phenomenex prodigy ODS 3 column (250mm×4.6mm,5μm).The mobile phase,MeOH-pH 4.0 buffer solution (7∶3),was used at a rate of 1.0mL·min -1.The detection wavelength was 280nm and the external standard was adopted.Results:Under the condition of test,the retention time of mizolastine was about 8.6min.The intermediate,the pharmaceutical aids and the decomposition products could be well separated from mizolastine.The linear range was 3~24μg·mL -1 and the linear regression equation was A=100038.05 C+ 655.6 (r=0.99999).The lowest concentration of detection was 60ng·mL -1.RSD of intra-day and inter-day were 0.39% and 0.56% (n=5) respectively.RSD of repeatability was 0.56% (n= 9).The average recoveries of method were 99.47%~101.97% (n=5) and the average recovery of preparation simulating test was 100.04%(n=9).Conclusion:The method developed is accurate and reliable.It is very suitable for the stability study of mizolastine sustained-release tablet.
出处 《中国新药杂志》 CAS CSCD 北大核心 2003年第7期556-558,共3页 Chinese Journal of New Drugs
关键词 咪唑斯汀 缓释片 高效液相色谱法 稳定性 mizolastine sustained-release tablet HPLC stability
  • 相关文献

参考文献4

  • 1国家药典委员会.中华人民共和国药典[S].北京:化学工业出版社,2000.附录:63,64.
  • 2李杰.皿治林[J].中国新药杂志,2001,10(5):383-385. 被引量:6
  • 3Simons FE, Simons KJ. Clinical Pharmacology of new histamine H1 receptor antagonists[J].Clin Pharmacokinet, 1999, 36 ( 5 ) :329 - 352.
  • 4Simons FE.Mizolastine:antihisamine activity from preclinical data to clinical evaluation[J].Clin Exp Allergy,1999,29(Suppl 1):S3-S8

二级参考文献9

  • 1[1]Simons FER.Mizolastine:antihistamine activity from preclinical data to clinical evaluation[J].Clin Exp Allergy,1999,29(Suppl)∶1-3.
  • 2[2]Michel L,Dubertret L,Jean-Louis F,et al.Modulation of IgE-dependent hypersensitivity reaction by mizolastine:inhibition of antigen-induced soluble ICAM-1 release[J].J Invest Dermatol,1997,108∶822.
  • 3[3]Praksh A,Lamb HM.Mizolastine:a review of its use in allergic rhinitis and chronic idiopathic urticaria[J].Biodrug,1998,10(1)∶42-59.
  • 4[4]Scadding GK,Tasman AJ,Murrieta-Aguttes M,et al.Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis[J].J Int Med Res,1999,27(6)∶273-285.
  • 5[5]Wedi B,Novacovic V,Komemer M,et al.Chronic urticaria serum induces histamine release,leukot-riene production,and basophil CD63 surface expression-inhibitory effects of anti-inflammatory drugs[J].J Allergy Clin Immunol,2000,105∶552-560.
  • 6[6]Pichat P,Angel I,Arbilla S.Anti-inflammatory properties of Mizolastine after administration on arachidonic acid-induced cutaneous reaction in the rat[J].Arzneim-Forsch/Drug Res,1998,48(1)∶173-178.
  • 7[7]Simons FER,Simons LJ.Clinical pharmacology of new histamine H1 receptor antagonists[J].Clin Pharmacokinet,1999,36(5)∶329-352.
  • 8[8]Leynadier F,Duarte-Risselin C,Murrieta M.Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria[J].Eur J Dermatol,2000,10∶205-211.
  • 9[9]Dubertret L,Murrieta Aguttes M.Efficacy and safety of mizolastine 10mg in placebo-controlled comparison with loratadine in chronic idiopathic urticaria[J].Journal of the European Academy of Dermatology and Venereology,1999,12∶16-24.

共引文献131

同被引文献23

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部